Prognostic Significance of Tumor Deposits in Stage III Colon Cancer
- 213 Downloads
The American Joint Committee on Cancer includes extranodal tumor deposits in the tumor–node–metastasis classification of colon cancer. However, it is unclear how tumor deposits compare with lymph node metastases in prognostic significance. This study evaluated the survival impact of tumor deposits relative to lymph node metastases in stage III colon cancer.
The US National Cancer Database (2010–2012) was reviewed for resectable stage III adenocarcinoma of the colon, and stratified by presence of tumor deposits and lymph node metastases. Univariate and multivariate survival analyses were performed.
Of 6424, 10.1% had both tumor deposits and lymph node metastases [5-year survival (5YS) 40.2%], 2.5% had tumor deposits alone (5YS 68.1%), and 87.4% had lymph node metastases alone (5YS 55.4%). Patients with lymph node metastases alone tended to have a greater number of lymph nodes retrieved (20.9 versus 18.8, p = 0.0126) and were more likely to receive adjuvant therapy (66.9 vs 58.0%, p = 0.003) than those with only tumor deposits. Patients with both had significantly worse survival at all T stages (p < 0.05, all). There was no significant difference in survival between tumor deposits alone and lymph node metastases alone at any T stage (p > 0.8, all). After controlling for patient, disease, and treatment characteristics, patients with tumor deposits alone [hazard ratio (HR) 0.56, p = 0.001] or only lymph node metastases (HR 0.64, p < 0.001) were associated with improved survival relative to patients with both.
Concomitant presence of tumor deposits and lymph node invasion carries poor prognostic significance. Tumor deposits alone appear to have prognostic implications similar to lymph node invasion alone.
Conflict of interest
All authors declare that they have no conflict of interest.
The National Cancer Data Base (NCDB) is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. The CoC’s NCDB and the hospitals participating in the CoC NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.
- 2.Cancer AJCo. Cancer staging system 2017. https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx. Accessed 6 June 2017.
- 3.Network NCC. Colon cancer. Clinical Practice Guielines in Oncology (NCCN Guidelines). 2015; version 2.2016.Google Scholar
- 8.Cuccurullo V, Mansi L. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (7th edition). Eur J Nucl Med Mol Imaging. 2011;38(2):408-408.Google Scholar
- 18.J. Milburn Jessup RMG, Asare EA, Benson AB III, Brierley JD, George J, Chang VC, Compton CC, De Nardi P, Goodman KA, Donna Gress, Justin, Guinney LLG, Hamilton SR, Hanna NN, Kakar S, Kosinski LA, Serban Negoita SO, Overman MJ, Quirke P, Rohren E, Sargent DJ, Lynne T, Schumacher-Penberthy DS, Sinicrope FA, Steele SR, Stojadinovic A, Sabine Tejpar MRW, Welton ML, Washington MK. Colon and rectum. AJCC Cancer Staging Manual, 8th Edn. Chicago: American Joint Committee on Cancer; 2017.Google Scholar